Safety and effectiveness of intravenous tranexamic acid for posterior lumbar interbody fusion in patients on preoperative anticoagulants: a retrospective case–control study

Background: Tranexamic acid (TXA) is a hemostatic agent used in posterior lumbar interbody fusion (PLIF). However, reports on its use in patients on preoperative anticoagulants are scarce. This study evaluates the safety and efficacy of preoperative 1 g TXA in such patients. Methods: = 29). The main observation indicators included surgical time, intraoperative blood loss (IBL), postoperative drainage volume (PDV), number of blood transfusions, red blood cell count (RBC), hemoglobin (HB), and hematocrit (HCT) on the postoperative 1st, 4th, 7th, and last-test days. The secondary observation indicators included postoperative incision healing, number of lower limb deep vein thrombosis (DVT), prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen (FIB), platelet count (PLT) and postoperative hospital stay. Results: > 0.05). Conclusion: For patients undergoing PLIF with preoperative anticoagulation, TXA administration appears safe and significantly reduces perioperative blood loss.